[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cholesterol-lipidosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cholesterol-lipidosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100431831","phase-1-liver-adiposity-effects-on-pediatric-statin-100431831",false,"NCT04903223","Liver Adiposity Effects on Pediatric Statin","Effects of Pediatric Liver Adiposity on Statin Disposition and Response","Inclusion Criteria:\n\n* 8-21 years\n* LDL cholesterol \\>130mg\u002Fdl (\\>95% percentile)\n* SLCO1B1 c.521TT genotype\n* Provide informed permission-assent(\\\u003C18 yrs.) or consent (≥18 yrs.)\n* Fasting overnight (\\~8 hrs.)\n* Enrolled in Cardiology Pharmacogenomic Repository\n\nExclusion Criteria:\n\n* Pregnancy\n* Non-fasting\n* Non-removable metal in body or MRI unsafe\n* Currently on statin therapy and unwilling to wash out of statin therapy for at least 4 weeks prior to Visit 1 and throughout the duration of the study.\n* Underlying unrepaired congenital or acquired cardiovascular defects or repaired congenital or acquired cardiovascular defects with hemodynamically significant residual disease.\n* History of underlying or laboratory evidence of underlying intestinal, metabolic, autoimmune, renal disease that can alter rosuvastatin disposition\\* (absorption, metabolism, distribution, or clearance)\n* Pharmacotherapy that interacts with statins (OATP1B1 inducers\u002Finhibitors) \\*\n* Inability to swallow a tablet\n* \\>5x the age-specific upper limit of normal for AST, ALT, total and conjugated bilirubin\n* Diarrhea in the last 24 hours\n* Anything that would exclude a participant from completing an MRI, such as pacemakers, claustrophobia, or body habitus (e.g., weight greater than 350 lbs.)",true,"ALL","8 Years","21 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","Single center, open-label, prospective investigation to quantify the effects hepatocellular fat has on hepatic statin transport and response in children and adolescents in obese and non-obese children and adolescents 8-21 years of age with normal, wild-type SLCO1B1 c.521TT genotype that are dosed rosuvastatin",[28],"Cholesterol; Lipidosis","RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":33},"2021-04-01",{"date":37,"type":22},"2027-03-31",{"name":39,"class":40},"Children's Mercy Hospital Kansas City","OTHER"]